Cantor Fitzgerald Predicts Higher Earnings for Zai Lab

Zai Lab Limited (NASDAQ:ZLAB) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Zai Lab in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.82) per share for the year, up from their previous estimate of ($1.46). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The business had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million.

A number of other equities research analysts have also issued reports on ZLAB. JPMorgan Chase & Co. upped their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, March 13th. Scotiabank assumed coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target for the company. Finally, Bank of America restated a “neutral” rating and set a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Zai Lab Stock Up 2.2%

Shares of NASDAQ:ZLAB opened at $28.75 on Wednesday. Zai Lab has a 52-week low of $16.01 and a 52-week high of $39.77. The stock has a market cap of $3.17 billion, a P/E ratio of -10.38 and a beta of 1.04. The business has a fifty day moving average of $32.20 and a two-hundred day moving average of $29.69.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ZLAB. Principal Financial Group Inc. purchased a new stake in shares of Zai Lab in the 4th quarter valued at $46,172,000. Raymond James Financial Inc. purchased a new stake in Zai Lab during the fourth quarter worth about $1,032,000. Alberta Investment Management Corp boosted its stake in shares of Zai Lab by 42.9% in the fourth quarter. Alberta Investment Management Corp now owns 232,293 shares of the company’s stock valued at $6,084,000 after purchasing an additional 69,740 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Zai Lab by 28.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company’s stock valued at $4,801,000 after purchasing an additional 41,128 shares in the last quarter. Finally, FMR LLC increased its stake in Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company’s stock worth $143,403,000 after buying an additional 4,830,646 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00. Following the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $17,032,212.99. This represents a 9.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Yajing Chen sold 924 shares of Zai Lab stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $33.11, for a total transaction of $30,593.64. Following the completion of the sale, the chief financial officer now owns 27,047 shares of the company’s stock, valued at $895,526.17. This trade represents a 3.30% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,133 shares of company stock valued at $7,416,861. 13.88% of the stock is currently owned by insiders.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.